GSK press releases Follow Exdensur (depemokimab) approved in China for the treatment of severe asthma Exdensur is the first and only ultra-long-acting biologic in China for the treatment of severe asthma with an eosinophilic phenotype. https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-china-for-the-treatment-of-severe-asthma/ gsk.com
